(NASDAQ: FHTX) Foghorn Therapeutics's forecast annual revenue growth rate of 18.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.72%.
Foghorn Therapeutics's revenue in 2025 is $24,518,000.On average, 12 Wall Street analysts forecast FHTX's revenue for 2025 to be $1,800,875,798, with the lowest FHTX revenue forecast at $1,358,927,475, and the highest FHTX revenue forecast at $2,770,730,405. On average, 12 Wall Street analysts forecast FHTX's revenue for 2026 to be $2,014,978,978, with the lowest FHTX revenue forecast at $0, and the highest FHTX revenue forecast at $3,562,731,207.
In 2027, FHTX is forecast to generate $2,314,304,951 in revenue, with the lowest revenue forecast at $1,108,405,264 and the highest revenue forecast at $3,633,985,831.